Skip to content

Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways

Safety and Efficacy of Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways: a Randomized Comparative Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04361006
Enrollment
30
Registered
2020-04-24
Start date
2018-10-01
Completion date
2021-02-01
Last updated
2023-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Accessory Pathway, Cardiac Arrhythmias, Wolf Parkinson White Syndrome

Keywords

para-hisian, radiofrequency, cryoablation, accessory pathway, electrophysiology

Brief summary

A randomized pilot study to evaluate safety and efficacy endpoints for treatment of para-hisian accessory pathways according to two different strategies of lesion formation. These patients will be divided into 2 groups with different strategies of treatment: group 1 treated with radiofrequency (RF) ablation, group 2 with cryotherapy (CRYO). The primary outcome will be the recurrence rate of accessory pathway conduction after one year of follow-up. Secondary endpoints will be immediate success and rate of permanent atrioventricular (AV) block.

Detailed description

This is a randomized study on the safety and efficacy for percutaneous ablation of para-hisian accessory pathways according to two different modalities: radiofrequency (RF) or cryotherapy. Thirty patients with symptomatic or high-risk para-hisian accessory pathways, documented by previous electrophysiological study (EPS), referred to percutaneous catheter ablation, will be enrolled in this trial. After informed consent, these patients will be randomized in 2 groups with different current established strategies of invasive treatment. Group I: electrophysiological mapping and ablation with radiofrequency (RF) focal lesion formation. Group II: electrophysiological mapping and ablation with cryotherapy (CRYO) focal lesion formation. The primary outcome will be the recurrence rate of accessory pathway conduction after one year of follow-up. Secondary endpoints will be immediate success and rate of permanent atrioventricular (AV) block.

Interventions

DEVICERadiofrequency (RF)

Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.

DEVICECryotherapy (CRYO)

Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.

Sponsors

InCor Heart Institute
CollaboratorOTHER
University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with para-hisian accessory pathways, diagnosed by electrophysiological study (EPS), with indication of invasive treatment according to current guidelines. Patients should be willing and able to sign an informed consent form, and to undergo all procedures described in both the study protocol and the consent form.

Exclusion criteria

* Previous cryotherapy ablation; * Previous extensive radiofrequency ablation (including aortic cusp mapping); * Age below twelve years; * Severe coagulation disorder; * Pregnancy; * Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
One-year recurrence rateOne yearRecurrence rate of accessory pathway conduction, as assessed by follow-up Clinical recording and event monitoring external device (Holter/Looper).

Secondary

MeasureTime frameDescription
Immediate success rateTime span between vein puncture (start of procedure) and sheath removal (end of procedure), comparing with baseline rhythmMensuration of immediate success at the EP lab after ablation therapy is finished, defined by elimination of accessory pathway and/or noninducibility of arrhythmias at the end of procedure, as assessed by standard electrophysiological maneuvers. If an evidence of accessory pathway conduction still remains at the end of procedure it will count as an unsuccessful case. Does not take into account recurrences after the end of procedure, e.g. in the hospital ward before discharge.
Rate of atrioventricular blockup to 24 hoursSafety outcome of any permanent atrioventricular (AV) block that occurred immediately after ablation start or during hospital admission.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026